Canagliflozin Tablets

Description

Canagliflozin Film-Coated Tablets (100 mg / 300 mg)

Healthy Inc is a specialized global supplier and exporter of advanced endocrinology, cardiology, and targeted metabolic therapeutics. We provide ultra-high-purity, kinetically stabilized Canagliflozin Tablets (100 mg / 300 mg), manufactured in WHO–GMP certified, high-precision oral solid dosage facilities. This “SGLT2 Inhibitor & Glucuretic Agent” is a massive-volume, high-tier export to diabetic centers, nephrology clinics, and government health ministries, serving as the globally mandated intervention for Type 2 Diabetes Mellitus (T2DM) and the reduction of major cardiovascular events.

Product Overview

This formulation operates as a non-insulin-dependent metabolic regulator. Unlike traditional drugs that force the pancreas to work harder, Canagliflozin utilizes the kidneys as a “safety valve,” physically removing excess glucose from the body through the urine.

• Mechanism 1 (SGLT2 Inhibition): Canagliflozin selectively inhibits the Sodium-Glucose Co-transporter 2 (SGLT2) in the proximal renal tubules. This protein is responsible for reabsorbing 90% of filtered glucose back into the blood. By blocking it, the drug lowers the renal threshold for glucose, forcing its excretion.

• Mechanism 2 (Osmotic Diuresis & BP Reduction): Because glucose carries water and sodium with it into the urine, Canagliflozin acts as a mild diuretic. This lead to a sustained reduction in Systolic Blood Pressure and a decrease in preload/afterload on the heart, protecting patients from heart failure.

• Mechanism 3 (Caloric Loss & Weight Management): Every gram of glucose excreted represents roughly 4 calories. Daily treatment typically results in the loss of 60–100 grams of glucose, leading to a “Metabolic Bonus” of modest weight loss, which is critical for type 2 diabetics.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments containing other active substances – Diabetes/Metabolic)

• CAS Number: 842133-18-0 (Canagliflozin)

• Dosage Form: Film-Coated Tablet (Immediate Release)

• Packaging: Alu-Alu Blisters. Protects the hemi-hydrate crystal structure from environmental humidity across Zone IVb tropical climates.

Manufacturing Authority & Compliance

• API Purity & Chiral Integrity: We utilize advanced chiral synthesis and HPLC monitoring to ensure the absolute purity of the Canagliflozin Hemi-hydrate, preventing the formation of inactive isomers and ensuring consistent clinical potency.

• Moisture-Controlled Processing: Our facility maintains Relative Humidity (RH) < 30% during the tableting of SGLT2 inhibitors to prevent the hydrate form from losing molecular water, which can affect the dissolution profile.

Dosage & Administration

• Standard Dosing: 100 mg once daily, taken before the first meal of the day.

• Renal Function Requirement (CRITICAL): The efficacy of Canagliflozin is dependent on kidney function. It is generally not initiated in patients with an $eGFR < 30 \text{ mL/min/1.73 m}^2$.

• Hydration Mandate: Patients must maintain adequate fluid intake to prevent volume depletion and hypotension.

Safety Warning: Increased risk of Genital Mycotic Infections (yeast infections) and UTIs due to glycosuria. Monitor for Euglycemic Ketoacidosis (DKA with normal blood sugar). Patients with a history of foot ulcers should be monitored closely for the risk of lower-limb amputations.

Global Export & Contract Manufacturing

Healthy Inc is a premier Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for modern SGLT2 inhibitors. Whether you are a Government Tender Supplier for diabetic programs in Africa or a B2B Pharma Marketplace partner in the CIS, we ensure secure, WHO-GMP compliant delivery.